Ilene Ceil Weitz, MD

Professor of Clinical Medicine (Part-Time)

Image of Ilene Ceil Weitz, MD
Is this your profile? Click to edit

Overview

Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.

Dr. Weitz earned her medical degree at Medical College of Pennsylvania in Philadelphia, followed by an internship and residency in internal medicine at Cedars-Sinai Medical Center. She conducted a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California.

Dr. Weitz is a member of the Academy-Simmons College Honor Society, Alpha Omega Alpha, American Medical Womens Association, Los Angeles County Medical Women’s Association, Alumni Associations of Medical College of Pennsylvania and Cedars-Sinai Medical Center, American Society of Hematology, and American Society of Clinical Oncology. She received the Morris Press Humanism Award in 1987 and the “Golden Apple” Outstanding Physician Educator Award in 1990 from Cedars-Sinai Medical Center, as well as the Outstanding Voluntary Faculty Award in the Division of Hematology from USC School of Medicine. Dr Weitz has delivered nationwide lectures and has been published in numerous journals, including American Journal of Clinical Pathology, Hepatology, and Journal of Clinical Oncology, American Journal of Hematology.. She has also contributed eight book chapters or reviews.

Dr. Weitz’ research and clinical interests include hematologic disorders such as anemias, thrombocytopenia and white blood cell disorders, paroxysmal nocgturnal hemoglobinurua (PNH), immune mediated anemias and thrombocytopenia, thrombosis and hemostasis.

Awards

  • Simmons College: Academy Honor Society, 1971
  • Alpha Omega Alpha: Elected Member, 1976
  • Cedars-Sinai Medical Center: Morris Press Humanism Award, 1987
  • Cedars-Sinai Medical Center: Golden Apple Outstanding Physician Educator Award, 1990
  • Division of Hematology, Keck School of Medicine: Outstanding Voluntary Faculty, 1996

Publications

  • Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy. Hemasphere. 2026 Jun; 10(6):e70384.. View in PubMed
  • Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape. Clin Adv Hematol Oncol. 2025 Jun; 23.. View in PubMed
  • Complement inhibitors: a significant advance in the treatment of PNH. Clin Adv Hematol Oncol. 2025 Jun; 23.. View in PubMed
  • Practical approach to managing PNH: Q&A. Clin Adv Hematol Oncol. 2025 Jun; 23.. View in PubMed
  • Monotherapy with terminal pathway C5 inhibitors. Clin Adv Hematol Oncol. 2025 Jun; 23.. View in PubMed
  • Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. EClinicalMedicine. 2024 Aug; 74:102733.. View in PubMed
  • Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension. EClinicalMedicine. 2024 Aug; 74:102732.. View in PubMed
  • Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study. Ann Hematol. 2024 May; 103(5):1803.. View in PubMed
  • Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 2024 Dec; 29(1):2329030.. View in PubMed
  • Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023 10 10; 7(19):5890-5897.. View in PubMed